A Phase 2 interventional study of Selatogrel 8 mg and Selatogrel 16 mg in Acute Myocardial Infarction, sponsored by Viatris Innovation GmbH. Completed at 6 sites in 3 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-07-29.
Sponsored by Viatris Innovation GmbH (part of Viatris Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Myocardial Infarction with a site in Switzerland — 14 open to participants now, 20 under way, 5 of them phase 3. Myocardial Infarction · Switzerland.
Among the 69 studies in Myocardial Infarction with a site in Switzerland, this one is the 45th largest by enrollment of the 51 interventional ones that give a count, is one of 3 that started in 2018, is one of 7 in phase 2, and was the 37th registered.
2,274 studies on the registry are indexed under Myocardial Infarction; 375 are open to participants now.
Browse Myocardial Infarction studies →14 of the 69 studies in Myocardial Infarction with a site in Switzerland are open now. Recruiting first, the newest first:
École Supérieure de Soins Ambulanciers - College of Higher Education in Prehospital Care · Sites in Switzerland
Ages 18+ · Healthy volunteers
Fondazione Don Carlo Gnocchi ETS · Sites in Switzerland, Belgium, Italy and 1 more country
Ages 18+
Novo Nordisk A/S · Sites in Switzerland, Austria, Denmark and 3 more countries
Ages 18+
University Hospital, Basel, Switzerland · Sites in Switzerland
Ages 18+
Cardiocentro Ticino · Sites in Switzerland
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 257 Myocardial Infarction studies recruiting now, 173 (67%) set no upper age limit and 26 (10%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is below the median of 150 across 1,317 interventional studies indexed under Myocardial Infarction.
Median enrollment 334 across the 51 interventional studies, 1,526 across the 18 observational. Of the 44 that completed or were terminated, 9 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 69 have an industry lead sponsor. The 10 most frequent:
This study is registered under Viatris Innovation GmbH, one of the names counted as Viatris Inc.. Under that name alone:
Viatris Innovation GmbH is the lead sponsor of 24 studies on the registry; 3 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.
Viatris Inc. has 4 studies filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
7 of the studies in Myocardial Infarction with a site in Switzerland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04957719Phase 3Viatris Innovation GmbHSelatogrel Outcome Study in Suspected Acute Myocardial Infarction | 2027-07 |
| NCT07810686École Supérieure de Soins Ambulanciers - College of Higher Education in Prehospital CareSmartphone AI Assistance for Prehospital ECG Interpretation | 2026-11-30 |
| NCT05859620University Hospital, Basel, SwitzerlandImplementation of a Clinical Screening and Response System for Cardiac Complications After Noncardiac Surgery | 2026-12 |
| NCT04988672Luzerner KantonsspitalOPTIMISER Registry - A Prospective Cohort Study to Describe the OPTIMal Management and Outcomes of PatIents PreSEnting With Acute MyocaRdial Infarction | 2026-12-31 |
| NCT07252856Fondazione Don Carlo Gnocchi ETSTranscultural Digital Solutions in Phase III Cardiac Rehabilitation | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 69 studies in Myocardial Infarction with a site in Switzerland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this study is to find out how fast a drug called selatogrel (ACT-246475) can prevent platelets from binding together. This study will also help to find out more about the safety of this new drug. The drug selatogrel (ACT-246475) will be used in 2 different doses (8 mg or 16 mg) and will be administered in the thigh.
This study is planned in patients presenting with Acute Myocardial Infarction (AMI) scheduled for an invasive strategy. Platelet activation and thrombus formation play a pivotal role in the pathophysiology of acute coronary syndrome. Early platelet inhibition has been shown to reduce the risk of recurrent events after a myocardial infarction.
The screening period starts when the participant provides informed consent and ends with participant's randomization. Eligible participants had an acute myocardial infarction (AMI; ST-segment elevation myocardial infarction [STEMI] or non-ST-elevation myocardial infarction [NSTEMI]), a life-threatening condition, and will therefore fulfill the ICH-GCP definition of vulnerable subjects ("persons in emergency situations"). Accordingly, a specific process for obtaining consent in compliance with local regulations and approved by the independent ethics committee will be implemented.
The study will be performed during a participant's hospital stay related to the qualifying AMI.
Standard treatment of AMI is allowed including anticoagulants. Ticagrelor will be the only oral P2Y12 receptor antagonist allowed to be initiated during the study and its administration will be possible only after selatogrel administration. Use of fibrinolytics or GPIIb/IIIa inhibitors will be prohibited unless required for bail-out. All other standard-of-care treatments for AMI will be allowed without restriction.
The treatment period starts with the participant's randomization and ends after the end-of-study assessments, approximately 48 hours after the administration of a single study treatment dose.
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Selatogrel (ACT-246475) is given as a single subcutaneous dose of 8 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.
Drug: Selatogrel 8 mg
Selatogrel (ACT-246475) is given as a single subcutaneous dose of 16 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.
Drug: Selatogrel 16 mg
Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water and further diluted with 1 mL sodium chloride (NaCl) 0.9%.
Also known as: ACT-246475
Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water for injection.
Also known as: ACT-246475
Number of Participants With a Pharmacodynamic Response as Assessed by the Inhibition of Platelet Aggregation
The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using the VerifyNow® assay. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU).The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU less than 100 at 30 minutes post-dose was counted as a participant that had a pharmacodynamic response.
Time frame: 30 minutes after the administration of the subcutaneous injection
Number of Participants (Per-protocol Subgroup) With a Pharmacodynamic Response as Assessed by the Inhibition of Platelet Aggregation
The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU). The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU of less than 100 starting at 30 minutes post-dose was counted as a participant that had a pharmacodynamic response.
Time frame: 30 minutes after the administration of the subcutaneous injection
Number of Participants With a Pharmacodynamic Response Within the First Hour as Assessed by the Inhibition of Platelet Aggregation
The purpose of this supportive analysis was to assess the effect when relaxing the time of a PRU \< 100, i.e., considering as a response a PRU \< 100 at 15, 30 or 60 min. post injection. The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using the VerifyNow® assay. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU).The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU less than 100 post-dose was counted as a participant that had a pharmacodynamic response.
Time frame: pre-dose, 15, 30 and 60 minutes after the administration of the subcutaneous injection
Absolute Platelet Reactivity (P2Y12 Reaction Units) Over Time
The pharmacodynamic response assessed by the inhibition of adenosine diphosphate (ADP)-mediated platelet aggregation was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test. The results are expressed as P2Y12 reaction units (PRU).
Time frame: pre-dose, 15, 30 and 60 minutes after administration of the subcutaneous injection
Maximum Selatogrel Plasma Concentration (Cmax)
The Cmax is the peak concentration of selatogrel in the plasma after subcutaneous injection. The pharmacokinetic parameters of selatogrel (ACT-246475) were derived by non-compartmental analyses of the plasma concentration-time profiles.
Time frame: pre-dose, 15, 30 and 60 minutes and 8 hours after the administration of the subcutaneous injection
Time to Reach Maximum Selatogrel Plasma Concentration (Tmax)
Time after subcutaneous injection to reach the maximum observed selatogrel plasma concentration (Cmax).
Time frame: pre-dose, 15, 30 and 60 minutes and 8 hours after the administration of the subcutaneous injection
The study was conducted between 10 July and 10 November 2018. Seven sites were initiated. Six sites in 3 countries screened and randomized 48 participants.
| Milestone | Selatogrel 8 mg | Selatogrel 16 mg |
|---|---|---|
| Started | 25 | 23 |
| Completed | 24 | 23 |
| Not completed | 1 | 0 |
| Withdrew: Not treated for administrative reasons | 1 | 0 |
| Milestone | Selatogrel 8 mg | Selatogrel 16 mg |
|---|---|---|
| Started | 24 | 23 |
| Modified full analysis set (mfas) | 23 | 22 |
| Per protocol set | 20 | 20 |
| Completed | 24 | 23 |
| Not completed | 0 | 0 |
The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using the VerifyNow® assay. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU).The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU less than 100 at 30 minutes post-dose was counted as a participant that had a pharmacodynamic response.
| Count of participants | Selatogrel 8 mg | Selatogrel 16 mg |
|---|---|---|
| Number of Participants With a Pharmacodynamic Response as Assessed by the Inhibition of Platelet Aggregation | 21 | 21 |
The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU). The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU of less than 100 starting at 30 minutes post-dose was counted as a participant that had a pharmacodynamic response.
| Count of participants | Selatogrel 8 mg | Selatogrel 16 mg |
|---|---|---|
| Number of Participants (Per-protocol Subgroup) With a Pharmacodynamic Response as Assessed by the Inhibition of Platelet Aggregation | 18 | 19 |
The purpose of this supportive analysis was to assess the effect when relaxing the time of a PRU \< 100, i.e., considering as a response a PRU \< 100 at 15, 30 or 60 min. post injection. The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using the VerifyNow® assay. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU).The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU less than 100 post-dose was counted as a participant that had a pharmacodynamic response.
| Count of participants | Selatogrel 8 mg | Selatogrel 16 mg |
|---|---|---|
| pre-dose | 1 | 0 |
| 15 minutes post-dose | 18 | 21 |
| 30 minutes post-dose | 21 | 21 |
| 60 minutes post-dose | 18 | 22 |
The pharmacodynamic response assessed by the inhibition of adenosine diphosphate (ADP)-mediated platelet aggregation was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test. The results are expressed as P2Y12 reaction units (PRU).
| P2Y12 reaction units (PRU) | Selatogrel 8 mg | Selatogrel 16 mg |
|---|---|---|
| pre-dose | 194 (159 to 213) | 181 (148 to 213) |
| 15 minutes post-dose | 51 (4 to 208) | 9 (2 to 282) |
| 30 minutes post-dose | 59 (2 to 135) | 9 (2 to 117) |
| 60 minutes post-dose | 9 (2 to 116) | 7 (1 to 228) |
The Cmax is the peak concentration of selatogrel in the plasma after subcutaneous injection. The pharmacokinetic parameters of selatogrel (ACT-246475) were derived by non-compartmental analyses of the plasma concentration-time profiles.
| ng/mL | Selatogrel 8 mg | Selatogrel 16 mg |
|---|---|---|
| Maximum Selatogrel Plasma Concentration (Cmax) | 390.1 (206 to 848) | 672.6 (276 to 1180) |
Time after subcutaneous injection to reach the maximum observed selatogrel plasma concentration (Cmax).
| hours | Selatogrel 8 mg | Selatogrel 16 mg |
|---|---|---|
| Time to Reach Maximum Selatogrel Plasma Concentration (Tmax) | 1.00 (0.50 to 1.27) | 0.97 (0.25 to 1.15) |
The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU). The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU of less than 100 starting at 30 minutes post-dose was counted as a participant that had a pharmacodynamic response.
| Count of participants | Selatogrel 8 mg | Selatogrel 16 mg |
|---|---|---|
| Age less than 55 years old | 3 | 4 |
| Age 55 years and older | 18 | 17 |
| Male | 14 | 17 |
| Female | 7 | 4 |
| Body Mass Index less than 25 | 5 | 8 |
| Body Mass Index less than 25 and up to 30 | 8 | 9 |
| Body Mass Index greater than 30 | 8 | 4 |
| Diabetes mellitus at baseline | 8 | 5 |
| No diabetes mellitus at baseline | 13 | 16 |
| Chronic kidney disease at baseline | — | 3 |
| No Chronic kidney disease at baseline | 21 | 18 |
| STEMI at baseline | 14 | 11 |
| NSTEMI at baseline | 7 | 10 |
Collected over Treatment emergent adverse events (TEAEs) were those adverse events with onset after study drug administration and up to 48 hours after study treatment administration.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Selatogrel 8 mg | 0/24 (0%) | 1/24 (4.2%) | 12/24 (50%) |
| Selatogrel 16 mg | 0/23 (0%) | 1/23 (4.3%) | 7/23 (30.4%) |
| Event | Selatogrel 8 mg | Selatogrel 16 mg |
|---|---|---|
| Ventricular tachycardiaCardiac disorders | 1/24 | 1/23 |
| Event | Selatogrel 8 mg | Selatogrel 16 mg |
|---|---|---|
| Ventricular tachycardiaCardiac disorders | 3/24 | 2/23 |
| DyslipidaemiaMetabolism and nutrition disorders | 3/24 | 2/23 |
| Aortic stenosisVascular disorders | 0/24 | 1/23 |
| Cardiac failureCardiac disorders | 0/24 | 1/23 |
| Mitral valve stenosisCardiac disorders | 0/24 | 1/23 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/24 | 1/23 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/24 | 1/23 |
| DizzinessNervous system disorders | 0/24 | 1/23 |
| Confusional statePsychiatric disorders | 0/24 | 1/23 |
| Herpes zosterInfections and infestations | 0/24 | 1/23 |
Full Analysis Set (all participants that were treated).
| Age, Categorical(Participants) | Selatogrel 8 mg | Selatogrel 16 mg | Total |
|---|---|---|---|
| Full Analysis Set — <=18 years | 0 | 0 | 0 |
| Full Analysis Set — Between 18 and 65 years | 9 | 8 | 17 |
| Full Analysis Set — >=65 years | 15 | 15 | 30 |
| Per Protocol Set — <=18 years | 0 | 0 | 0 |
| Per Protocol Set — Between 18 and 65 years | 9 | 7 | 16 |
| Per Protocol Set — >=65 years | 11 | 13 | 24 |
| Age, Continuous(years) | Selatogrel 8 mg | Selatogrel 16 mg | Total |
|---|---|---|---|
| Full Analysis Set | 65.5 ± 11.3 | 68.0 ± 10.3 | 66.7 ± 10.8 |
| Per Protocol Set | 64.5 ± 12.1 | 67.9 ± 10.3 | 66.2 ± 11.3 |
| Sex: Female, Male(Participants) | Selatogrel 8 mg | Selatogrel 16 mg | Total |
|---|---|---|---|
| Full Analysis Set — Female | 8 | 5 | 13 |
| Full Analysis Set — Male | 16 | 18 | 34 |
| Per Protocol Set — Female | 5 | 4 | 9 |
| Per Protocol Set — Male | 15 | 16 | 31 |
| Ethnicity (NIH/OMB)(Participants) | Selatogrel 8 mg | Selatogrel 16 mg | Total |
|---|---|---|---|
| Full Analysis Set — Hispanic or Latino | 0 | 0 | 0 |
| Full Analysis Set — Not Hispanic or Latino | 24 | 23 | 47 |
| Full Analysis Set — Unknown or Not Reported | 0 | 0 | 0 |
| Per Protocol Set — Hispanic or Latino | 0 | 0 | 0 |
| Per Protocol Set — Not Hispanic or Latino | 20 | 20 | 40 |
| Per Protocol Set — Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Selatogrel 8 mg | Selatogrel 16 mg | Total |
|---|---|---|---|
| Full Analysis Set — American Indian or Alaska Native | 0 | 0 | 0 |
| Full Analysis Set — Asian | 1 | 2 | 3 |
| Full Analysis Set — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Full Analysis Set — Black or African American | 0 | 0 | 0 |
| Full Analysis Set — White | 22 | 21 | 43 |
| Full Analysis Set — More than one race | 0 | 0 | 0 |
| Full Analysis Set — Unknown or Not Reported | 1 | 0 | 1 |
| Per Protocol Set — American Indian or Alaska Native | 0 | 0 | 0 |
| Per Protocol Set — Asian | 1 | 2 | 3 |
| Per Protocol Set — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Per Protocol Set — Black or African American | 0 | 0 | 0 |
| Per Protocol Set — White | 18 | 18 | 36 |
| Per Protocol Set — More than one race | 0 | 0 | 0 |
| Per Protocol Set — Unknown or Not Reported | 1 | 0 | 1 |
| Region of Enrollment(participants) | Selatogrel 8 mg | Selatogrel 16 mg | Total |
|---|---|---|---|
| Belgium | 7 | 7 | 14 |
| Israel | 1 | 0 | 1 |
| Switzerland | 16 | 16 | 32 |
| Body Mass Index(kilograms per square meter) | Selatogrel 8 mg | Selatogrel 16 mg | Total |
|---|---|---|---|
| Full Analysis Set | 28.00 ± 4.83 | 26.78 ± 3.74 | 27.40 ± 4.33 |
| Per Protocol Set | 27.64 ± 4.88 | 26.67 ± 3.79 | 27.16 ± 4.34 |
| Medical history risk factors at baseline(Participants) | Selatogrel 8 mg | Selatogrel 16 mg | Total |
|---|---|---|---|
| Diabetes mellitus | 8 | 5 | 13 |
| Chronic Kidney disease | 0 | 3 | 3 |
| Hypertension | 15 | 12 | 27 |
| Dyslipidemia | 8 | 10 | 18 |
4 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2018 to primary completion in Nov 2018, 4 months.
Results were first posted in Aug 2021, 2 years 9 months after primary completion. A results delay was requested in Aug 2019.
Of 45 phase 2 interventional studies under Myocardial Infarction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 42. This study's 4 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selatogrel